Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2013

View Archived Issues

New biomarkers for celiac disease reported

Researchers prepare and test labeled iRGD peptides as cancer diagnostics

Phase I evaluation of oligonucleotide therapy in patients with ALS

Dainippon Sumitomo Pharma presents novel selective 11-beta-HSD1 inhibitor

New CCR1 and CCR6 receptor inhibitors for the treatment of rheumatoid arthritis described

Results presented from head-to-head phase II study of pateclizumab versus adalimumab

Roche presents final stage 1 results from obinutuzumab study

Portola Pharmaceuticals patents novel tyrosine-protein kinase inhibitors

Merck KGaA discloses new protein kinase inhibitors

Johnson & Johnson to acquire Aragon Pharmaceuticals

Inovio Pharmaceuticals reports data from preclinical trial of its H7N9 DNA vaccine

Oxygen Healthcare Research divulges novel histamine H3 receptor ligands

Ambrx and Zhejiang Medicine collaborate on ARX-788 for breast cancer

Shionogi to collaborate with Irish universities

Athera Biotechnologies obtains E.U. grants for its antibody therapy

EryDex obtains orphan drug designation for ataxia telangiectasia in Europe

Aeroquin shows sustained therapeutic efficacy in phase III trial for cystic fibrosis

MannKind completes phase III study of Afrezza in type 2 diabetes

Eli Lilly exercises rights to Transition Therapeutics' TT-401

Nitto Denko's lidocaine patch receives additional indication approval in Japan

Abilify granted additional indication approval as adjunctive therapy for depression

Summit achieves milestone in development of C. difficile antibiotic

Silence Therapeutics advances phase Ib/IIa study of RNAi therapeutic

FDA accepts Ruconest BLA for review

Takeda launches Nesina and fixed-dose combinations for type 2 diabetes in the U.S.

Canadian acceptance of MycoTool for release testing of Roche product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...